21-hydroxylase deficiency epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}} | {{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}} | ||
{{CMG}} | {{CMG}} | ||
Line 9: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The incidence of 21-hydroxylase deficient CAH detectable in childhood is about 1 in 15,000 births. The severe salt-wasting form accounts for the majority of these cases, which is high enough that many states and countries routinely include it in mandated [[newborn screening]] tests. The incidence of simple virilizing CAH is about 1 in 60,000 children. | The incidence of 21-hydroxylase deficient CAH detectable in childhood is about 1 in 15,000 births. The severe salt-wasting form accounts for the majority of these cases, which is high enough that many states and countries routinely include it in mandated [[newborn screening]] tests. The incidence of simple [[virilizing]] CAH is about 1 in 60,000 children. | ||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] |
Revision as of 15:53, 3 September 2015
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters |
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
21-hydroxylase deficiency epidemiology and demographics On the Web |
American Roentgen Ray Society Images of 21-hydroxylase deficiency epidemiology and demographics |
FDA on 21-hydroxylase deficiency epidemiology and demographics |
CDC on 21-hydroxylase deficiency epidemiology and demographics |
21-hydroxylase deficiency epidemiology and demographics in the news |
Blogs on 21-hydroxylase deficiency epidemiology and demographics |
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
Risk calculators and risk factors for 21-hydroxylase deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Epidemiology and Demographics
The incidence of 21-hydroxylase deficient CAH detectable in childhood is about 1 in 15,000 births. The severe salt-wasting form accounts for the majority of these cases, which is high enough that many states and countries routinely include it in mandated newborn screening tests. The incidence of simple virilizing CAH is about 1 in 60,000 children.